{"schema_version":"1","generated_at":"2026-10-30T04:25:36.491Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jayne-gurtler","json_url":"https://www.findmykol.com/kol/jayne-gurtler/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jayne-gurtler","name":"Jayne Gurtler","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Universal Sensors","institution_url":"https://www.findmykol.com/institution/universal-sensors","city":"Metairie","state":"LA","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1396712808","openalex":"A5110532224"},"summary":"Jayne Gurtler is an Oncology physician affiliated with Universal Sensors. OpenAlex indexes 42 publications with 1,506 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":42,"cited_by_count":1506,"h_index":9,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":27,"program_years":{"first":2021,"last":null},"rows_total":45,"shown":3,"withheld":42,"rows":[{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":108.72,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396712808"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":99.95,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396712808"},{"payer":"ARRAY BIOPHARMA INC","program_year":2025,"amount_usd":95.58,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396712808"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1396712808","source":"payments"},"prescribing":{"data_year":2024,"areas_total":9,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":54.3,"classes_total":7,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":20.1,"drugs":[{"name":"Letrozole","share_pct":79.5},{"name":"Anastrozole","share_pct":20.5}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":20,"drugs":[{"name":"Calquence","share_pct":55.8},{"name":"Brukinsa","share_pct":18.2},{"name":"Tagrisso","share_pct":10.3},{"name":"Ibrance","share_pct":9.1},{"name":"Imatinib Mesylate","share_pct":6.7}],"max_beneficiaries":null}]},{"area":"Blood & clotting","share_pct":9.6,"classes_total":2,"classes":[{"class":"Vitamin K antagonist","setting":"prescribed","share_pct":5.3,"drugs":[{"name":"Warfarin Sodium","share_pct":100}],"max_beneficiaries":null},{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":4.2,"drugs":[{"name":"Eliquis","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":8.8,"classes_total":4,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":3,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":20},{"class":"Corticosteroid","setting":"prescribed","share_pct":2.4,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":12}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":10,"shown":5,"withheld":5,"matched_by":"OpenAlex author record","recent":[{"title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","year":2017,"journal":"Breast Cancer Research and Treatment","source_url":"https://doi.org/10.1007/s10549-017-4537-5","status":"verified"},{"title":"Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.","year":2016,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.tps4134","status":"verified"},{"title":"Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.","year":2016,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.tps4135","status":"verified"},{"title":"P-282 JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer","year":2016,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1093/annonc/mdw199.272","status":"verified"},{"title":"P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer","year":2016,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1093/annonc/mdw199.271","status":"verified"}],"source":"works"},"contact":{"address_1":"3939 HOUMA BLVD","address_2":"SUITE 6","city":"Metairie","state":"LA","zip":"700062931","phone":"504-885-0577","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1396712808","source":"identity"},"similar":[{"name":"Ravi Jandhyala","slug":"ravi-jandhyala","institution":"Universal Sensors","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/ravi-jandhyala","json_url":"https://www.findmykol.com/kol/ravi-jandhyala/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":42,"publications":5}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2009-04-03","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}